Rocket Pharmaceuticals
RCKT
15 hedge funds and large institutions have $52.5M invested in Rocket Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 15 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DPA
Devon Park Associates
|
+$19M |
| 2 |
RCP
Rho Capital Partners
New York
|
+$16.8M |
| 3 |
Jennison Associates
New York
|
+$5.87M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$4.89M |
| 5 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$4.11M |
Top Sellers
RCKT Hedge Fund Activity: Q1 2015 in Review
15 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q1 2015, worth a combined $52.5M.
Buyers outnumbered sellers: 15 funds opened new RCKT positions and 0 closed out — a net gain of 15 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Devon Park Associates, opening a new position worth an estimated $19M.
- 15 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q1 2015, up from 0 in Q4 2014.
- Funds reported $52.5M of Rocket Pharmaceuticals stock for Q1 2015.
- 15 funds opened new Rocket Pharmaceuticals positions in Q1 2015 and 0 closed out, a net change of +15 holders.
- The largest Rocket Pharmaceuticals buyer in Q1 2015 was Devon Park Associates, an estimated $19M added.
Based on aggregated 13F filings for Q1 2015.